To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. About Bioventus Investor and Media Inquiries: Dave Crawford 919-474-6787 Dave.Crawford@bioventus.com DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, ...

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. About Bioventus Investor and Media Inquiries: Dave Crawford 919-474-6787 Dave.Crawford@bioventus.com DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market opens on Tuesday, August 6, ...

Bioventus (BVS) makes minimally invasive treatments that engage and enhance the body's natural healing process. Bioventus is focusing on accelerating top-line growth, enhancing operational efficiency and improving profitability, cash flow, and liquidity. Its medical products are focused on three segments — Pain Treatments, Restorative Therapies and Surgical Solutions. It is seeing double-digit revenue growth in both Pain Treatments and Surgical Solutions, which has improved its profitability. It delivered 1 ...

Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential. These companies operate in a variety of industries, including technology and healthcare. They offer a unique opportunity to profit from rapid revenue growth, strong financial stability and well-thought-out development strategies. With a robust organic revenue increase in the first quarter and a solid focus on the hyaluronic acid (HA) busines ...

Chase Knickerbocker - Craig-Hallum Robbie Marcus - JPMorgan Chase & Co. Caitlin Cronin - Canaccord Genuity Thank you, Andrea, and good morning, everyone, and thanks for joining us. It is my pleasure to welcome you to the Bioventus 2024 first-quarter earnings conference call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO. Rob will begin his remarks with an update on our 2024 priorities in our business. Mark will provide detail of our first-quarte ...

Exhibit 99.1 DURHAM, NC – May 7, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. First Quarter 2024 Financial Results: *See below under "Use of Non-GAAP Financial Measures" for more details. The following table represents net sales by geographic region, and by business, for the three months ended March 30, 2024 and April 1, 2023: (a) Sales from the SonicOne produ ...

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 a ...

Innovations For Active Healing Agenda and Speakers Mark Singleton Senior Vice-President and Chief Financial Officer Forward Looking Statements and Use of Estimates Use of Estimates Unless otherwise indicated, information contained in this presentation concerning our industry, competitive position and the markets in which Bioventus operates is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from pu ...

Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Rob Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin d - Canaccord Genuity Operator Good day, and welcome to the Bioventus Inc. Fourth Quarter 2023 Earnings Conference Call. [Operator Instruct ...

SECURITIES AND EXCHANGE COMMISSION ________________ ________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37844 (Exact Name of Registrant as Specified in Its Charter) | --- | |-----------------------------| | | | | | Accelera ...